Glucocorticoids can inhibit inflammation by abrogating the activity of NF-κB, a family of transcription factors that regulates the production of proinflammatory cytokines. To understand the molecular mechanism of repression of NF-κB activity by glucocorticoids, we performed a high-throughput siRNA oligo screen to identify novel genes involved in this process. Here, we report that loss of p53, a tumor suppressor protein, impaired repression of NF-κB target gene transcription by glucocorticoids. Additionally, loss of p53 also impaired transcription of glucocorticoid receptor (GR) target genes, whereas upstream NF-κB and glucocorticoid receptor signaling cascades remained intact. We further demonstrate that p53 loss severely impaired glucocorticoid rescue of death in a mouse model of LPS shock. Our findings unveil a new role for p53 in the repression of NF-κB by glucocorticoids and suggest important implications for treatment of the proinflammatory microenvironments found in tumors with aberrant p53 activity.
Glucocorticoids can inhibit inflammation by abrogating the activity of NF-κB, a family of transcription factors that regulates the production of proinflammatory cytokines. To understand the molecular mechanism of repression of NF-κB activity by glucocorticoids, we performed a high-throughput siRNA oligo screen to identify novel genes involved in this process. Here, we report that loss of p53, a tumor suppressor protein, impaired repression of NF-κB target gene transcription by glucocorticoids. Additionally, loss of p53 also impaired transcription of glucocorticoid receptor (GR) target genes, whereas upstream NF-κB and glucocorticoid receptor signaling cascades remained intact. We further demonstrate that p53 loss severely impaired glucocorticoid rescue of death in a mouse model of LPS shock. Our findings unveil a new role for p53 in the repression of NF-κB by glucocorticoids and suggest important implications for treatment of the proinflammatory microenvironments found in tumors with aberrant p53 activity. N uclear factor kappa B (NF-κB) is a family of transcription factors that have an essential regulatory function in inflammation, the immune response, cell proliferation, and apoptosis (1) . Constitutive activation of the NF-κB pathway is often associated with cancer and chronic inflammatory diseases such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis (RA), and asthma. NF-κB family members include p50 (NF-κB1), p52 (NF-κB2), p65 (RELA), RELB, and c-REL, and these subunits bind to form homo-and heterodimerized complexes (2, 3) . In the classical NF-κB signaling pathway, the p65 and p50 subunits heterodimerize and are sequestered in an inactive complex in the cytoplasm bound to IκBα (2, 4, 5) . Upon activation by proinflammatory stimuli such as tumor necrosis factor-alpha (TNFα) or lipopolysaccharide (LPS), the IκB kinase (IKK) complex phosphorylates IκBα (6) , targeting it for ubiquitination and proteasomal degradation (7) , allowing the p65/50 complex to translocate to the nucleus where p65 can bind to the promoter regions of its target genes. p65 phosphorylation by protein kinase A (PKA) or mitogen-and stress-activated protein kinase-1 (MSK-1) at serine (Ser)276 (8, 9) and also by ζPKC at serine 311 (10) then aids in the recruitment of transcriptional activation machinery, leading to transcription of NF-κB target genes.
The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor superfamily and plays a critical role in metabolism, development, reproduction, and homeostasis. Intracellular GR resides in the cytoplasm in an inactive state, bound to a low molecular weight protein (p23), immunophilin FKBP51, and a variety of heat shock proteins (hsps), including hsp90, hsp70, hsp56, and hsp40 (11, 12) . Upon passive diffusion and subsequent binding by glucocorticoids, GR can dissociate from its inhibitory complex and translocate to the nucleus via active transport by dynein (13) . In the nucleus, GR homodimers bind to glucocorticoid response elements (GREs) in the promoter regions of GR target genes to activate their transcription. GR can also bind as a monomer to negative (n)GREs in promoter regions of genes to inhibit their transcription (14, 15) . Dexamethasone (Dex), a synthetic glucocorticoid that activates GR upon binding, is a commonly prescribed antiinflammatory drug used to provide relief from inflammation, infection, and immune diseases associated with NF-κB up-regulation (16) (17) (18) (19) (20) . Although the precise molecular details of how glucocorticoids repress NF-κB activity are not fully elucidated, a number of mechanisms have been proposed which include (i) increased expression of IκBα by GR, which increases the sequestration of p65/ p50 heterodimers in the cytoplasm and limits NF-κB translocation to the nucleus and subsequent activation of its target genes (21, 22) ; (ii) GR binding as a monomer to the promoter regions of NF-κB target genes, thus inhibiting NF-κB binding and transcriptional activation; (iii) GR and NF-κB competition for Creb-binding protein and p300, members of the transcriptional activation machinery; (iv) GR recruitment of histone deacetylase complexes to the promoter regions of NF-κB target genes; and (v) GR and NF-κB interaction in the nucleus, where GR tethers NF-κB, thereby inhibiting transcriptional activation of its target genes (23) (24) (25) (26) (27) .
Some of the proposed mechanisms of repression are likely to be cell-type specific or context specific, and a universal mechanism of repression has yet to be clearly established. Discovery of novel genes involved in NF-κB repression by GR, elucidation of their mechanisms, and identification of universal mechanisms, will be critical for a more comprehensive understanding of how GR inhibits NF-κB. To address these issues, we used a RNAi-based screening approach to identify novel genes that regulate GR repression of NF-κB and, in follow-up experiments, validate p53 as a novel regulator of NF-κB repression by GR both in vitro and in vivo.
Results p53 Is Required for Repression of NF-κB Activity. We developed and optimized a high-throughput luciferase assay using four siRNA oligo library collections to search for potential genes that play a role in NF-κB repression by the glucocorticoid receptor. The number of genes represented and characteristics of two kinase libraries and two druggable genome libraries used for screening are summarized in Table S1 . siRNA oligos from each of the libraries were prearrayed into 384-well plates and reverse transfected for 48 h into 293T cells stably transfected with a NF-κB luciferase reporter (Fig.  1A ). Cells were then treated for 24 h with 10 ng/mL TNF ± 1 μM Dex in duplicate and assayed for luciferase activity (Fig. 1A) .
The efficacy of the screen was determined by luciferase analysis of siGR, sip65, si luciferase, and mock controls added to each of the 384-well plates. Expected luciferase activity trends were seen upon knockdown of GR, p65, and luciferase in all four siRNA oligo libraries, providing validity that the screen could be used to successfully identify potential genes of interest ( Fig. S1 A  and B) . Redundant siRNA activity (RSA) analysis is an acceptable statistical method to interpret data from large-scale RNAi screens, while minimizing off-target effects (28) . Of the 8,515 genes tested, we identified 290 genes of interest by performing three RSA analyses: one analyzing data from the two kinase libraries, one from the two druggable genome libraries, and one from data collected from all four library collections ( Fig. S2 A-C) . Each gene of interest was specific to the TNF + Dex condition and did not significantly affect luciferase activity by TNF alone. Genes in each list were rank ordered according to log P value, and the number one gene of interest, based on log P value by RSA analysis using all four library collections, was p53 (log P < −27), a tumor suppressor gene that plays a critical role in cell cycle regulation and apoptosis and is mutated in over 50% of human cancers (Fig. S2A) .
Gene ontology (GO) analysis of the 290 genes showed enrichment for 114 biological processes, P values <0.001. A number of homeostasis, developmental, and metabolic processes, as well as apoptotic, cell cycle, and kinase activity categories were among the list of overrepresented pathways (Fig. S3A) . KEGG pathway analysis showed enrichment for 29 pathways with P values <0.05, including MAPK signaling (a pathway with known p53 and GR interactions), apoptosis, cell cycle, and 13 cancer-related pathways (Fig. 1B) . We also performed Reactome analysis to determine which pathways were overrepresented in our list of 290 genes and to confirm results from KEGG pathway analysis. A total of 181 genes, of the 290 analyzed, were not represented in the database, suggesting that a number of uncharacterized and/or unstudied genes may play a role in GR repression of NF-κB. Reactome analysis revealed that 109 events with P values <0.05 were overrepresented, including a number of events related to metabolism and MAPK signaling, as well as NF-κB related signaling events (Fig. S3B) , confirming results obtained by KEGG pathway analysis (Fig. 1B) . Through the STRING database, we analyzed proteinprotein interactions for genes overrepresented in the MAPK and cancer pathways by KEGG analysis (Fig. S4) . We included GR in each STRING analysis to map known interactions with GR and the genes of interest shown in each pathway. p53, shown in red, was found in both the MAPK signaling pathway (Fig. S4 , Upper) and the cancer pathways (Fig. S4, Lower) .
Sixteen wells containing a siRNA oligo targeting p53 were included as a control in the Invitrogen kinase library collection. When siRNAs were rank ordered according to fold change between the TNF and TNF + Dex conditions, 14 of the 16 wells were near or at the top of the list. To visualize this observation, each siRNA's average normalized raw value for the TNF and TNF + Dex condition was plotted and 10 wells containing sip53 were indicated in red, illustrating that wells containing sip53 are significant outliers compared with other siRNAs (Fig. 1C) .
To confirm initial screening results, we transfected 293T cells stably expressing a NF-κB luciferase reporter with a Rous sarcoma virus (RSV)-lacZ construct and either sip53, siGR, sip65, si luciferase, or a siRNA control, and treated cells with 10 ng/mL TNF ± 1 μM Dex. p53 knockdown was confirmed in this cell line by qPCR (Fig. S5A ). Untransfected cells and cells transfected with a negative control siRNA exhibit a 38 and 48% respective decrease in NF-κB luciferase activity upon Dex addition (Fig.  1D , first two conditions). In contrast, cells transfected with sip53 and siGR exhibit only a 6 and 18% respective decrease in NF-κB luciferase repression upon Dex addition (Fig. 1D , third and fourth conditions). As expected, a decrease in NF-κB luciferase activity is seen upon knockdown of p65 and luciferase. Our preliminary conclusion is that a decrease in p53 expression impairs GR-mediated repression of NF-κB luciferase activity in these cells.
Validation of p53 as a Mediator of NF-κB Repression by GR. To validate p53's effect on glucocorticoid repression of NF-κB activity in a more physiologically relevant cell line, we transduced human monocytic THP-1 cells with a NF-κB luciferase reporter (Fig.  S6A ), and either a lentiviral shp53-GFP vector or a lentiviral GFP vector as control (Fig. S6B) , and treated cells with 10 ng/ mL TNF ± 1 μM Dex. GFP control cells showed more than a 3.5-fold decrease in NF-κB luciferase activity upon Dex addition ( Fig. 2A, Left) . However, this repression upon Dex addition is lost in cells expressing shp53 ( Fig. 2A , Right). p53 knockdown was confirmed by qPCR (Fig. S5B) .
To further confirm the effect of p53 loss on NF-κB repression by GR, we transduced WT and p53KO MEF cells with the lentiviral NF-κB luciferase reporter and treated cells with 10 ng/ mL TNF ± 1 μM Dex. WT cells show more than a 1.3-fold decrease in NF-κB luciferase activity upon Dex addition (Fig. 2B , Left). In contrast, NF-κB activity in p53KO MEF cells is completely restored in the presence of Dex (Fig. 2B , Right). p53 loss was confirmed in these cells by qPCR (Fig. S5C) . On the basis of these results, we conclude that knockdown or loss of p53 impairs GR repression of NF-κB.
To determine whether we could rescue Dex repression, we transduced p53KO MEF cells with a lentiviral-WT p53 construct and treated cells with 10 ng/mL TNF ± 1 μM Dex. p53KO MEF cells, transduced with a lentiviral vector making WT p53, show substantial restoration of repression of NF-κB luciferase activity upon treatment with Dex (Fig. 2C) .
p53 activation is often regulated by complex formation with murine double minute-2 (MDM2), an E3 ubiquitin ligase that inhibits p53 transcriptional activity (29) . Nutlin-3 is a protease inhibitor that was found to specifically disrupt the MDM2/p53 interaction, consequently stabilizing p53 (30) . To determine the effect of p53 stabilization on GR repression of NF-κB, THP-1 cells stably expressing a NF-κB luciferase reporter were treated for 24 h with 10 μM nutlin-3, then treated for an additional 24 h with 10 ng/mL TNF ± 1 μM Dex. Cells that were not treated with nutlin had an average of less than 1.7-fold decrease in NF-κB luciferase activity upon Dex treatment (Fig. S7, Left) . In contrast, cells treated with nutlin exhibited an average of more than a 2.3-fold decrease in NF-κB luciferase activity upon Dex treatment (Fig. S7, Right) . These results suggest that stabilization of p53 enhances GR repression of NF-κB.
To further investigate the role of p53 in GR repression of NF-κB, we isolated bone marrow-derived macrophages (BMDMs) from WT and p53KO mice, treated cells with 10 ng/mL TNF ± 1 μM Dex or 10 ng/mL LPS ± 1 μM Dex for 2 h, and analyzed the mRNA levels of NF-κB target genes. p53 loss was confirmed in these cells by qPCR (Fig. S5D ). An increase in cyclooxygenase (Cox2) mRNA levels is seen upon LPS stimulation, and a more than twofold repression is seen upon Dex addition (Fig. 2D,  Left) . However, Dex can no longer regulate Cox2 mRNA levels in p53KO cells. Cells also exhibited an increase in monocyte chemotactic protein-1 (MCP-1) mRNA levels upon LPS stimulation, and a more than twofold decrease upon Dex addition (Fig. 2D, Right) . However, Dex repression of MCP-1 mRNA levels was impaired in the absence of p53. In addition, p53 loss impaired Dex repression of both TNF and LPS-induced mRNA expression levels of IP-10, a NF-κB-specific target gene. We conclude that p53 loss disrupted repression of NF-κB target gene transcription by GR. Interestingly, Dex could still repress LPSinduced TNF mRNA expression in the absence of p53, suggesting that p53 regulates Dex-mediated transcriptional repression of some, but not all NF-κB target genes.
p53 Does Not Alter Upstream NF-κB Signaling. To understand the mechanism of involvement of p53 in Dex-induced suppression of NF-κB activity, we next analyzed the effect of p53 loss on the upstream NF-κB signaling cascade. WT and p53KO MEF cells were treated with 10 ng/mL TNF ± 1 μM Dex for 10, 20, 30, or 60 min, and the effect of p53 loss on IκBα degradation and phosphorylation kinetics was determined by immunoblot analysis. In WT cells, IκBα total protein levels decrease starting at the 10-min time point upon TNF addition, and the protein is resynthesized by the 60-min time point (Fig. 3A, Top, lanes 1-5) . The degradation observed at the 10-min time point correlates to the increase in IκBα phosphorylation (Fig. 3A, Middle, lane 2) . Degradation and phosphorylation remain unchanged in WT cells upon Dex addition (Fig. 3A , Top and Middle, lanes 6-10), and these kinetics are unchanged in p53KO cells (Fig. 3A , Top and Middle, lanes [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Protein levels were normalized to p65 loading control (Fig. 3A , Bottom) and quantified using ImageJ (Fig. S8A) . We conclude that p53 loss does not alter either IκBα phosphorylation or degradation, two essential steps in NF-κB activation. We next evaluated the effect of p53 loss on p65 translocation to the nucleus. BMDMs were isolated from WT and p53KO mice, treated for 30 min with 10 ng/mL TNF ± 1 μM Dex, and fixed with 4% paraformaldehyde. p65 nuclear accumulation is seen upon TNF treatment and remains unchanged upon Dex addition in WT cells (Fig. 3B, Left) . Similarly, we can see nuclear accumulation of endogenous p65 after treatment with TNF and after treatment with TNF + Dex in p53KO cells (Fig. 3B, Right) . Quantification of the number of cells with nuclear p65 staining in each condition showed little or no difference (Fig. S8B) . We conclude that p53 loss does not alter p65 translocation to the nucleus.
p65 is phosphorylated at serine 276 by PKA and MSK-1 and at serine 311 by ζPKC, two sites of phosphorylation that are important for NF-κB transcriptional activation. To analyze the effect of p53 loss on endogenous p65 phosphorylation at these two sites, we performed endogenous immunofluorescence on WT and p53KO BMDMs treated with 10 ng/mL TNF ± 1 μM Dex for 30 min. Using either Ser311-or Ser276-specific phosphoantibodies, the extent of p65 accumulated in the nucleus upon treatment with TNF or TNF + Dex, in either WT or p53KO BMDMs, remains unchanged ( Fig. 3 C and D) . Together, these results suggest that p53 loss does not alter GR repression of NF-κB by affecting phosphorylation at these two crucial sites required for p65 transcriptional activation.
p53 Does Not Alter Upstream GR Signaling but Is Required for GRMediated Transcription. To determine the effect of p53 loss on endogenous GR translocation, BMDMs were isolated from WT and p53KO mice, treated for 30 min with 1 μM Dex, and fixed with 4% paraformaldehyde. GR nuclear accumulation is seen upon Dex treatment in both WT and p53KO cells (Fig. 4A) , suggesting that p53 loss does not play a role in GR nuclear translocation upon ligand stimulation.
We then evaluated the effect of p53 loss on GR-mediated transcription. WT and p53KO BMDMs were treated for 2 h with Dex and quantitative PCR was performed to analyze changes in GR target gene mRNA levels. In WT cells, there is significant increase in mRNA levels of GR target genes, Mt2 and Fkbp5, upon Dex addition (Fig. 4B) . In contrast, the increase in mRNA transcription levels of Mt2 and Fkbp5 upon Dex addition, is severely impaired in p53KO cells (Fig. 4B) .
We next wanted to analyze changes in mRNA levels of glucocorticoid-induced leucine zipper (GILZ), a transcription factor and transcriptional target of GR known to repress NF-κB upon treatment with Dex (31, 32) . WT and p53KO BMDMs were treated with 1 μM Dex for 30 min and 1, 2, 4, and 6 h, and GILZ mRNA levels were analyzed. Basal mRNA levels of GILZ were similar in WT and p53KO cells throughout the 6-h period (Fig.  4C) . However, Dex-induced expression of GILZ over time is impaired in p53KO cells compared with relative mRNA levels in WT cells (Fig. 4C) . From the cumulative results shown in Fig. 4 , we conclude that a loss of p53 impairs GR-dependent transcription.
In Vivo Suppression of NF-κB Activity by Glucocorticoids. To investigate the effect of p53 loss on GR repression of NF-κB in vivo, we developed a mouse model of LPS shock. WT and p53KO mice treated with 50 mg/kg LPS ± 10 mg/kg Dex by i.p. injection were monitored for death by LPS shock every 6 h for the first 54 h and every 24 h for the subsequent 4 d (7-d monitoring period total). All but one WT (n = 11) and all p53KO (n = 8) mice treated with LPS alone succumbed to LPS shock within 36 h of treatment (Fig. 5A) . The last surviving WT mouse treated with LPS died within 54 h (Fig. 5A) . Glucocorticoid treatment led to the survival of 9 out of 12 WT mice and, in contrast, only 3 of 14 p53KO mice treated with LPS + Dex survived (Fig. 5A) . The Kaplan-Meier survival curve shows these trends in Fig. 5A , as 75% of WT mice and only 21% of p53KO mice treated with Dex survived death by LPS shock.
We also analyzed the effect of p53 loss on LPS shock-induced reduction in body temperature. Body temperatures from WT (n = 3) and p53KO (n = 3) C57BL6 mice sham treated with PBS by i.p. were analyzed every 6 h over a 48-h period using a rectal thermometer probe. The maximum recorded temperature decrease over that period by one individual mouse was 1.1°C. Temperature measurements were also recorded every 6 h over a 48-h period and for every subsequent 24 h up to 5 d total for WT and p53KO mice treated with 50 mg/kg LPS ± 10 mg/kg Dex by i.p. injection. Eleven of 12 WT mice and all p53KO mice (n = 8) treated with LPS exhibited body temperature decreases of at least 12°C within 12 h (Fig. 5B) . Nine of 12 WT mice treated with LPS + Dex exhibited varying degrees of temperature decrease from LPS shock, but these mice recovered to within 1°C of their starting temperature within 5 d (Fig. 5C, Left) . In contrast, only 3 of 14 p53KO mice treated with LPS + Dex were able to recover to their starting temperature (Fig. 5C, Right) . From these results, we conclude that p53 loss impaired GR repression of NF-κB activity in vivo in a mouse model of LPS shock.
Discussion
The mechanisms explaining GR repression of NF-κB activity to suppress inflammation are complex and varied. Our RNAi screen identified p53 as a regulator of NF-κB repression by the glucocorticoid receptor, and we confirmed its biological significance using both in vitro and in vivo assays. Current insight into the relationship between p53 and GR is unclear. It has been suggested that p53 and GR interact with each other, thereby leading to the suppression of GR transcriptional activity (33) (34) (35) (36) (37) . However, most of these studies were performed using transfection and overexpression techniques, and none include data from primary cells or in vivo mouse models as shown here. Other groups have reported that suppression of p53 impairs GR function in the presence of Dex and that glucocorticoid treatment enhances p53 transcriptional activity (38, 39) . These findings reinforce our hypothesis that p53 is playing a modulatory role in GR function and transcriptional activation. In addition, patients with RA, an autoimmune disorder in which glucocorticoid treatment is often an ineffective antiinflammatory therapy, showed reduced p53 expression levels in blood mononuclear cells (40) and were also found to exhibit p53 mutations in synoviocytes (41) . The observations made in these clinical studies lend further credence to our findings, suggesting that nonfunctional p53 may correlate to the impaired glucocorticoid repression of inflammation seen in RA patients. Loss of p53 does not affect GR or NF-κB nuclear translocation ( Fig. 3B and Fig. 4A ), suggesting that p53 aids in GR repression of NF-κB when all three proteins are localized to the nucleus. Once all three proteins are in the nucleus, p53 may target GR to NF-κB, aiding in the complex formation between these two transcription factors, preventing binding to NF-κB sites (Fig. 5D, Left) . It is also possible that p53 interacts with GR and NF-κB directly, and that all three form a complex in the nucleus, which prevents binding of the NF-κB proteins to their cognate DNA binding site(s). We also confirm that p53 loss impairs GR transcription of its target genes (Fig. 4 B and C) . p53 may directly target GR to the promoter regions of its target genes or might also help to recruit transcriptional activation machinery to the promoter regions of GR target genes (Fig. 5D , Right). We cannot rule out the potential that p53 may be involved in removal of repressive complexes and/or recruitment of other coactivators as well. Although we have no formal proof that p53 transcriptional activation played a role in GR repression of NF-κB, we must consider the possibility that downstream targets of p53 may be involved in repression of NF-κB by GR.
Elucidating the exact mechanism that describes the role of p53 in GR repression of NF-κB is an important lingering question. Over half of the genes we identified as potential genes of interest were unrepresented in the STRING and/or Reactome databases, suggesting that a number of uncharacterized or unstudied genes may play a role in GR repression of NF-κB. This possibility is interesting, as these unique genes may represent a number of entirely new therapeutic targets and reveal unknown mechanisms of GR repression. Further studies are needed to investigate precisely how p53 functions in GR repression of NF-κB. To better understand the protein interactions of these three important transcription factors, mutagenesis studies, as well as endogenous immunoprecipitation and ChIP analyses, may help elucidate the domains involved and regions of interaction. In addition, it would also be interesting to determine whether the other two p53 protein family members, p63 or p73, play a similar role in GR repression of NF-κB, and to investigate whether p53 is also involved in repression of NF-κB by other nuclear hormone receptor family members.
Our discovery that p53 is a regulator of NF-κB repression by GR may have important therapeutic implications. The p53 tumor suppressor protein plays a critical role in the development of many human cancers and is often mutated or deleted, leading to tumor progression (42, 43) . NF-κB is often up-regulated in tumor cells deficient in p53 and in tumor cells that have other mutations, which lead to impaired p53 signaling. There is also growing evidence that NF-κB induction of inflammatory genes is an important component for tumor progression (44, 45) . Our findings suggest that NF-κB could be up-regulated in tumor cells, in part, because endogenous glucocorticoids, due to a loss of p53 function, can no longer efficiently repress NF-κB. In addition, glucocorticoid treatment, although a potent antiinflammatory therapy, has not been shown to significantly reduce inflammation in tumor cells. Our findings suggest that a possible explanation for why glucocorticoids cannot repress inflammation and NF-κB in these cells is, in part, because p53 signaling is deficient. We have unveiled a unique role for p53 in the repression of NF-κB by glucocorticoids in vitro and in vivo, a finding that ultimately has important implications for the study and treatment of the proinflammatory microenvironments found in tumors with aberrant p53 activity.
Materials and Methods
Luciferase Assays for Validation of Screen Results. (i) 293T cells stably transfected with a 3× NF-κB luciferase reporter were cotransfected with a RSVlacZ construct and sip53 oligo (Invitrogen), siGR (Invitrogen), sip65 (Invitrogen), si luciferase (Invitrogen), or a stealth RNAi negative universal control (Invitrogen). Forty-eight hours following transfection with Lipofectamine 2000, cells were treated with 10 ng/mL TNF ± 1 μM Dex for 24 h. Luciferase assay and normalization to lacZ transfection was then performed using Steady Glo (Promega) and Beta Glo (Promega) reagent. (ii) THP-1 cells were transduced with concentrated lentiviral 5×-NF-κB-luciferase-mPGKmcherry and EF1α-GFP or EF1α-shp53-GFP. Cells were sorted for the mcherry(+) and GFP(+) cell population. Cells were then treated with 10 ng/mL TNF ± 1 μM Dex for 6 h and luciferase assay was performed using Steady Glo reagent. (iii) WT and p53KO MEF cells were transduced with concentrated lentiviral 5×-NF-κB-luciferase-mPGK-mcherry and sorted for the mcherry(+) cell population. Cells were treated with 10 ng/mL TNF ± 1 μM Dex for 24 h and luciferase assay was performed using Steady Glo reagent. (iv) p53KO MEF cells were transduced with concentrated lentiviral 5×-NF-κB-luciferase-mPGK-mcherry and sorted for the mcherry(+) cell population. 
